Wake Forest University

Wake Forest University

Contents

Location
Physicians
NABTT Protocol Availability
Contact Information

Location

Wake Forest University
Medical Center Boulevard
Winston-Salem, NC 27157

Physician	Glenn Lesser, MD	Edward Shaw, MD	Stephen Tatter, MD, PhD
Specialty	Neuro-Oncology	Radiation Oncology	Neurosurgery
Address	Wake Forest University Comprehensive Cancer Center, Hem/Onc Medical Center Blvd. Winston-Salem, NC 27157-1082	Wake Forest University School of Medicine Dept. of Radiation Oncology Medical Center Blvd. Winston-Salem, NC 27157-1020	Wake Forest University School of Medicine Division of Neurosurgery Medical Center Blvd. Winston-Salem, NC 27157-1029
Phone Number	336-716-9527	336-716-4647	336-716-4047
Email	glesser@wfubmc.edu	eshaw@wfubmc.edu	statter@wfubmc.edu

Physician	Volker Stieber, MD
Specialty	Radiation Oncology
Address	Wake Forest University Dept. of Radiation Oncology Medical Center Blvd. Winston-Salem, NC 27157-1020
Phone Number	336-716-2987
Email	vstieber@wfubmc.edu

NABTT Protocol Availability

Class A: (Newly Diagnosed Glioblastoma Multiforme with Measurable Disease)

Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults with Newly Diagnosed Malignant Glioma

Class B: (Newly Diagnosed Glioblastoma Multiforme, Measurable/Non Measurable Disease)

Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma
A Safety Run-In/Randomized Phase II Trial of EMD 121974 in Conjunction with Concomitant and Adjuvant Temozolomide with Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme

Class C: (Recurrent High Grade Astrocytoma, with Measurable Disease)

Phase I Evaluation of the Safety of PS341 in the Treatment of Recurrent Gliomas
A Phase I/II Trial of BMS-247550 for Treatment of Patients with Recurrent High-grade Gliomas
A Phase I Trial of BAY 43-9006 for Patients with Recurrent or Progressive Malignant Glioma
A Phase I Open-label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients with MTAP-Deficient High Grade Recurrent Malignant Gliomas

Class D: (Locally Recurrent High Grade Astrocytoma)

An Open-label, Dose Confirmation and Dosimetry Study of Interstitial ¹³¹I-chTNT-1/B MAb (COTARA™) For the Treatment of Glioblastoma Multiforme (GBM) at 1^st or 2^nd Relapse

Class E: (Histology other than High Grade Astrocytoma)

A Phase II Study of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Patients with Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)

Class F: (Non-therapeutic Protocols)

A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas
Identification of Hypermethylated Serum Tumor DNA in High Grade Glioma Patients and Correlation with Magnetic Resonance Imaging Findings
CD4 Count and Risk of Infection in Patients with Brain Tumors

For information regarding the protocols available at this center, please contact:

Michele Harmon, RN
Research Nurse
Wake Forest University
Comprehensive Cancer Center
CSB 7th Floor, Hem/Onc Protocol Office
Medical Center Blvd
Winston-Salem, NC 27157-1082
Telephone: 336-716-1193
mharmon@wfubmc.edu

Charlotte, Miller, RN
Surgical Research Nurse
Wake Forest University
Division of Neurosurgery
Medical Center Blvd
Winston-Salem, NC 27157-1020
Telephone: 336-716-4031
chmiller@wfubmc.edu